Identification of a novel, selective GABAa α5 receptor inverse agonist which enhances cognition

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2227-2240

  Chambers, Mark S ^a   Atack, John R ^a   Broughton, Howard B ^a   Collinson, Neil ^a   Cook, Susan ^a   Dawson, Gerard R ^a   Hobbs, Sarah C ^a   Marshall, George ^a   Maubach, Karen A ^a   Pillai, Goplan V ^a   Reeve, Austin J ^a   MacLeod, Angus M ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 6,6 DIMETHYL 1 (PYRAZOL 3 YL) 3 (THIAZOL 2 YL)THIO 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; 6,6 DIMETHYL 1 (THIAZOL 2 YL) 3 (THIAZOL 2 YL)THIO 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; 6,6 DIMETHYL 3 (2 HYDROXYETHYL)THIO 1 (THIAZOL 2 YL) 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; 6,6 DIMETHYL 3 ISOPROPYLAMINO 1 (PYRAZOL 3 YL) 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; 6,6 DIMETHYL 3 METHYLTHIO 1 (PYRIDIN 2 YL) 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; 6,6 DIMETHYL 3 METHYLTHIO 1 (PYRIDIN 4 YL) 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; 6,6 DIMETHYL 3 METHYLTHIO 1 (THIAZOL 2 YL) 6,7 DIHYDRO 2 BENZOTHIOPHEN 4(5H) ONE; BENZOTHIOPHENE DERIVATIVE; CONVULSANT AGENT; FLUMAZENIL; L 655708; LIGAND; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COGNITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; HIPPOCAMPUS; LIGAND BINDING; MAZE TEST; MEMORY; NONHUMAN; RAT;

ANIMALS; BRAIN; CELL LINE; COGNITION; FEMALE; GABA AGONISTS; HIPPOCAMPUS; HUMANS; LIGANDS; MALE; MAZE LEARNING; MEMORY; MICE; NOOTROPIC AGENTS; OOCYTES; PATCH-CLAMP TECHNIQUES; PROTEIN SUBUNITS; RADIOLIGAND ASSAY; RATS; RECEPTORS, GABA-A; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIOPHENES; XENOPUS LAEVIS;

EID: 0038586580     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020582q     Document Type: Article

References (41)

1. Bormann, J. The 'ABC' of GABA receptors. Trends Pharmacol. Sci. 2000, 21, 16-19.
2. A receptors based on subunit composition. In GABA in the nervous system: The view at fifty years; Martin, D. L.; Olsen, R. W., Eds.; Lippincott, Williams & Wilkins: New York, 2001; pp 113-126.
3. A-receptor subtypes really occur in the brain? Trends Neurosci. 1996, 19, 139-143.
4. A receptors: Classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 1998, 50, 291-313.
5. Olsen, R. W.; Venter, J. C. Benzodiazepine/GABA receptors and chloride channels: Structural and functional properties; New York: Alan R. Liss Inc., 1986.
6. Cole, S. O. Effects of benzodiazepines on acquisition and performance: A critical assessment. Neurosci. Biobehav. Rev. 1986, 10, 265-272.
7. Ghoneim, M. M.; Mewaldt, S. P. Benzodiazepines and human memory: A review Anaesthesiology 1990, 72, 926-938.
8. Hagen, T. J.; Guzman, F.; Schultz, C.; Cook, J. M.; Skolnick, P.; Shannon, H. E. Synthesis of 3,6-disubstituted β-carbolines which possess either benzodiazepine antagonist or agonist activity. Heterocycles 1986, 24, 2845-2855.
9. A/benzodiazepine receptor subtype. Med. Chem. Res. 1995, 5, 700-709.
10. McNamara, R. K.; Skelton, R. W. Benzodiazepine receptor antagonists flumazenil and CGS 8216 and inverse agonist β-CCM enhance spatial learning in the rat: Dissociation from anxiogenic actions. Psychobiology 1993, 21 (2), 101-108.
11. Dorow, R.; Horowski, R.; Paschelke, G.; Amin, M.; Braestrup, C. Severe anxiety induced by FG 7142, a β-carboline ligand for benzodiazepine receptors. Lancet 1983, 2, 98-99.
12. Petersen, E. N. DMCM: A potent convulsive benzodiazepine receptor ligand. Eur. J. Pharmacol. 1983, 94, 117-124.
13. Little, H. J.; Nutt, D. J.; Taylor, S. C. Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling. Br. J. Pharmacol. 1984, 83, 951-958.
14. Sarter, M.; Bruno, J. P.; Berntson, G. G. Psychotogenic properties of benzodiazepine receptor inverse agonists. Psychopharmacology 2001, 156, 1-13.
15. A receptor subtypes. Nature 1999, 401, 796-800.
16. Low, K.; Crestani, F.; Keist, R.; Benke, D.; Brunig, I.; Benson, J. A.; Fritschy, J.-M.; Rulicke, T.; Bluethmann, H.; Mohler, H.; Rudolph, U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000, 290, 131-134.
17. A receptor α1 subtype. Nat. Neurosci. 2000, 3, 587-592.
18. A receptors have α5β3γ2 pharmacological characteristics. Mol. Pharmacol. 1998, 54, 928-933.
19. A receptor subtypes. Pharmacol. Rev. 1995, 47, 181-234.
20. A/BzR subtypes (α1β3γ2, α5β3γ2 and α6β3γ2) via a comprehensive ligand-mapping approach. J. Med. Chem. 2000, 43, 71-95.
21. (b) Masciadri, R.; Thomas, A. W.; Wichmann, J. Preparation of 9H-imidazo[1,5-a][1,2,4]triazolo-[4,3-d][1,4]benzodiazepines as alpha 5 subunit selective GABA A receptor inverse agonists. In PCT Int. Appl.; (F. Hoffmann-La Roche AG, Switz.). WO 02/040487.
22. (c) Masciadri, R.; Thomas, A. W.; Wichmann, J. Imidazo[1,5-a]pyrimido[5,4-d] benzodiazepine derivatives as GABA A receptor modulators. In PCT Int. Appl.; (F. Hoffmann-La Roche AG, Switz.). WO 02/094834.
23. A receptors which contain the α5 subunit. Neuropharmacology 1996, 35, 1331-1335.
24. A/BzR sites. Med. Chem. Res. 1999, 9, 71-88.
25. Chambers, M. S.; Atack, J. R.; Bromidge, F. A.; Broughton, H. B.; Cook, S.; Dawson, G. R.; Hobbs, S. C.; Maubach, K. A.; Reeve, A. J.; Seabrook, G. R.; Wafford, K.; MacLeod, A. M. 6,7-Dihydro-2-benzothiophen-4(5H)-ones: A novel class of GABA-A α5 receptor inverse agonists. J. Med. Chem. 2002, 45, 1176-1179.
26. Kearsley, S. K.; Sallamack, S.; Fluder, E. M.; Andose, J. D.; Mosley, R. T.; Sheridan, R. P. Chemical similarity using physiochemical property descriptors. J. Chem. Inf. Comput. Sci. 1996, 36, 118-127.
27. Patent EP 0601184. Inventor, Yoshitomi Pharmaceutical Ind. Ltd.
28. Available from Maybridge Chemical Co. Ltd., Trevillett, Cornwall, U.K.
29. A receptor. J. Neurochem. 2001, 77, 445-451.
30. Hadingham, K. L.; Garrett, E. M.; Wafford, K. A.; Bain, C.; Heavens, R. P.; Sirinathsinghji, D. J. S.; Whiting, P. J. Cloning of cDNAs encoding the human γ-aminobutyric acid type A receptor α6 subunit and characterization of the pharmacology of α6-containing receptors. Mol. Pharmacol. 1996, 49, 253-259.
31. A receptor subtypes. Mol. Pharmacol. 1993, 43, 240-244.
32. A receptors containing γ3 subunits. Eur. J. Pharmacol. 1995, 291, 301-309.
33. 2L subunits stably transfected into mouse fibroblast L-cells. Br. J. Pharmacol. 1992, 107, 732-737.
34. Radioligand binding and enzyme assays performed by MDS Pharma Services, PO Box 26-127, Taipei, Taiwan, R.O.C.
35. A receptors. Neuropsychopharmacology 1999, 20, 255-262.
36. Roberts, A. J.; Keith, L. D. Mineralocorticoid receptors mediate the enhancing effects of corticosterone on convulsion susceptibility in mice. J. Pharm. Exp. Ther. 1994, 270, 505-511.
37. Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11, 47-60.
38. Steele, R. J.; Morris, R. G. M. Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5. Hippocampus 1999, 9, 118-136.
39. A receptor. J. Neurosci. 2002, 22, 5572-5580.
40. A receptors. Proc. Natl. Am. Sci. 2002, 99, 8980-8985.
41. A receptors. Mol. Pharmacol. 1993, 43, 970-975.